Scaling new heights: Ionizable lipids for nanomedicine development, GMP manufacturing

After playing a crucial role in the COVID-19 pandemic response, lipid nanoparticle-encapsulated RNA (RNA-LNP) vaccines are quickly advancing through the clinical pipeline to address other infectious diseases. However, challenges―like limited access to ionizable lipids and formulation expertise―persist.

At Cytiva, we have developed an optimized ionizable lipid and LNP composition to streamline RNA delivery in nanomedicines, facilitating payload screening and LNP optimization. Our strategies also focus on the rapid progression of promising RNA-LNP drug candidates to clinical evaluation.

In this presentation, we take a closer look at how our collaboration with Replicate Bioscience helped deliver a self-replicating RNA (srRNA) vaccine with promising Phase 1 clinical data, showcasing a favorable safety profile and promising immune protection for a novel RNA-based vaccine.

Speaker
Martin Rabel